Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction

Alí Duarte-García, Juanita Romero-Díaz, Sandra Juárez, Alba Cicero-Casarrubias, Hilda Fragoso-Loyo, Carlos Núñez-Alvarez, Luis Llorente, Jorge Sánchez-Guerrero, Alí Duarte-García, Juanita Romero-Díaz, Sandra Juárez, Alba Cicero-Casarrubias, Hilda Fragoso-Loyo, Carlos Núñez-Alvarez, Luis Llorente, Jorge Sánchez-Guerrero

Abstract

Objective: To determine if cognitive dysfunction in patients with systemic lupus erythematosus (SLE) derives from an inflammatory process with continuing disease activity, and increased levels of autoantibodies and inflammatory molecules in serum and cerebrospinal fluid (CSF).

Methods: 100 randomly selected patients participating in an inception SLE cohort were studied. At entry into the cohort, a standardized medical history and extensive laboratory tests profile, including autoantibodies were completed. Follow-up occurred every 3-6 months with assessment of lupus characteristics, comorbidities, and treatment. After a mean follow-up of six-years, cross-sectional evaluation of cognitive function was done with standardized tests, and in a subset of patients an extended profile of autoantibodies, cytokines and chemokines was measured in serum and CSF.

Results: At enrollment into the cohort, patients were 26.4±8.2 years of age and lupus duration 5.3±3.7 months. Moderate/severe cognitive dysfunction was diagnosed in 16 patients; in comparison to patients with normal cognitive function, they had lower education 9 vs. 12 years (P = 0.006), higher body mass index 26.7 vs. 24.3 (P = 0.03), positive IgG anticardiolipin antibodies 50% vs 18% (P = 0.009), and a higher median number of concomitant NPSLE syndromes 3 vs. 1, (P = 0.04). The prevalence of cardiovascular-risk factors, other auto-antibodies, lupus activity, treatment, and incidence of critical events did not differ. In serum and CSF, the levels of autoantibodies, cytokines and chemokine were similar, only CCL2 was elevated in CSF [886.1 (374.9-1439.7) vs. 515.8 (3.2-1958.2) pg/mL, P = 0.04].

Conclusion: Scant evidence of inflammation in SLE patients with cognitive dysfunction was observed. Only a higher prevalence of IgG anticardiolipin antibodies in serum and increased levels of CCL2 in CSF were detected.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. ACR ad hoc committee on neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608. doi:
    1. Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992;19:562–7.
    1. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001;57:496–500.
    1. Brey R, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214–20.
    1. Murray SG, Yazdany J, Kaiser R, Criswell LA, Trupin L, Yelin EH, et al. Cardiovascular Disease and Cognitive Dysfunction in Systemic Lupus Erythematosus. Arthritis Care Res 2012;64:1328–33.
    1. Tomietto P, Annese V, D’Agostini S, Venturini P, La Torre G, De Vita S, et al. General and Specific Factors Associated With Severity of Cognitive Impairment in Systemic Lupus Erythematosus. Arthritis Rheum (Arthritis Care Res) 2007;57:1461–72.
    1. Ginsburg KS, Wright EA, Larson MG, Fossel AH, Albert M, Schur PH, et al. A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum 1992;35:776–82.
    1. Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairement in systemic lupus erythematosus. J Nerv Ment Dis 1986;174:357–64.
    1. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42–8.
    1. Saczynski JS, Jónsdóttir MK, Garcia ME, Jonsson PV, Peila R, Eiriksdottir G, et al. Cognitive Impairment: An Increasingly Important Complication of Type 2 Diabetes. Am J Epidemiol 2008;168:1132–9. doi:
    1. Monk TG, Weldon BC, Garvan CW, Dede DE, van der Aa MT, Heilman KM, et al. Predictors of Cognitive Dysfunction after Major Noncardiac Surgery. Anesthesiology 2008; 108:18–30. doi:
    1. Selnes OA, Gottesman RF, Grega MA, Baumgartner WA, Zeger SL, McKhann GM. Cognitive and Neurologic Outcomes after Coronary-Artery Bypass Surgery. N Engl J Med 2012;366:250–7. doi:
    1. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, et al. Long-Term Cognitive Impairement after Critical Illness. N Engl J Med 2013;369:1306–16. doi:
    1. Tiffin-Richards FE, Costa AS, Holschbach B, Frank RD, Vassiliadou A, Krüger T, et al. The Montreal Cognitive Assessment (MoCA)—A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients. PLoS One. 2014;9:e106700 doi:
    1. Panopalis P, Julian L, Yazdany J, Zell Gillis J, Trupin L, Hersh A, et al. Impact of Memory Impairment on Employment Status in Persons With Systemic Lupus Erythematosus. Arthritis Rheum 2007;57:1453–60. doi:
    1. Appenzeller S, Cendes F, Costallat LTL. Cognitive Impairment and Employment Status in Systemic Lupus Erythrmatosus: A Prospective Longitudinal Study. 2009;61:680–7.
    1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
    1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. Letter.
    1. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69:529–35. doi:
    1. Romero-Díaz J, Vargas-Vóracková F, Kimura-Hayama E, Cortázar-Benítez LF, Gijón-Mitre R, Criales S, et al. Systemic lupus erythematosus risk factors for coronary calcifications. Rheumatology (Oxford) 2012;51:110–9.
    1. Isenberg DA, Ramsey-Goldman R, Gladman D, Hanly JG. The Systemic Lupus International Collaborating Clinics (SLICC) group—it was 20 years ago today. Lupus. 2011;20:1426–32. doi:
    1. Urowitz MB, Gladman D, Ibañez D, Bae SC, Sánchez-Guerrero J, Gordon C, et al. Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus. Arthritis Care Res 2010;62:881–7.
    1. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.
    1. Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39:363–9.
    1. Kowal C, DeGiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe B, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA. 2006;103:19854–9. doi:
    1. Ibañez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Activity Index-2K is a predictor of outcome in SLE. J Rheumatol. 2005;32:824–7.
    1. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-Methyl-D-Aspartate Receptor Antibodies, Cognitive Dysfunction, and Depression in Systemic Lupus Erythematosus. Arthritis Rheum 2006;54:2505–14. doi:
    1. Cournot M, Marquié JC, Ansiau D, Martinaud C, Fonds H, Ferriéres J. Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology 2006;67:1208–14. doi:
    1. Gustafson D, Lissner L, Bengtsson C, Björkelund C, Skoog I. A 24-year follow-up of body mass index and cerebral atrophy. Neurology 2004;63:1876–81.
    1. Menon S, Jameson-Shortall E, Newman S.P, Hall-Craggs M.R., Chinn R., Isenberg D.A. A Longitudinal Study of Anticardiolipin Antibody Levels and Cognitive Functioning in Systemic Lupus Erythematosus. Arthritis Rheum 1999;42:735–41. doi:
    1. Hanly JG, Hong C, Smith S, Fisk JD. A Prospective Analysis of Cognitive Function and Anticardiolipin Antibodies in Systemic Lupus Erythematosus. Arthritis Rheum. 1999;42:728–34. doi:
    1. Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003;12:280–6. doi:
    1. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189–93. doi:
    1. Harrison MJ, Ravdin LD, Lockshin MD. Relationship Between Serum NR2a Antibodies and Cognitive Dysfunction in Systemic Lupus Erythematosus. Arthritis Rheum 2006;54:2515–22. doi:
    1. Yoshio T, Onda K, Nara H, Minota S. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2006;54:675–8. doi:
    1. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narváez A, Dávila-Maldonado L, Atisha-Fregoso Y, Llorente L, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007;56:1242–50. doi:
    1. Fragoso-Loyo H, Atisha-Fregoso Y, Llorente L, Sánchez-Guerrero J. Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 2013;52:2218–22.
    1. Little AR, Benkovic SA, Miller DB, O’Callaghan JP. Chemically induced neuronal damage and gliosis: enhanced expression of the proinflammatory chemokine, monocyte chemoattractant protein (MCP)-1, without a corresponding increase in proinflammatory cytokines. Neuroscience 2002;115:307–20.39.
    1. Madrigal JL, Caso JR.The chemokine (C-C motif) ligand 2 in neuroinflammation and neurodegeneration. Adv Exp Med Biol. 2014;824:209–19. doi:
    1. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 2004;43:1555–60.
    1. Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F.Cerebral and corpus callosum atrophy in systemic lupus erythematosus.Arthritis Rheum 2005;52:2783–9. doi:
    1. Kozora E, Arciniegas DB, Filley CM, Ellison MC, West SG,Brown MS, et al. Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus:preliminary data. Cogn Behav Neurol 2005; 18:159–62.
    1. Filley CM, Kozora E, Brown MS, Miller DE, West SG, Arciniegas DB, Grimm A, Zhang L. White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus. Cogn Behav Neurol. 2009; 22:38–44. doi:
    1. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One. 2012;7(1):e30525 doi:
    1. Kimura A, Yoshikura N, Hayashi Y, Inuzuka T. Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease. J Alzheimers Dis. 2018;61:581–588. doi:
    1. Fragoso-Loyo H, Cabiedes J, Orozco-Narváez A, Dávila-Maldonado L, Atisha-Fregoso Y, Diamond B et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One. 2008;3:e3347 doi:
    1. Denburg SD, Carbotta RM, Denburg JA. Cognitive impairment in systemic lupus erythematosus: A neuropsychological study of individuals and group deficits. Journal of Clinical and Neuropsychology. 1987;9:323–39.
    1. Glanz BI, Slonim D, Urowitz MB, Gladman DD, Gough J, MacKinnon A. Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus. Neuropsychiatry, Neuropsychology, & Behavioral Neurology. 1997;10:232–8.
    1. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1996;39:2035–45.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren